Agoracom Blog Home

Posts Tagged ‘stocks’

NORTHBUD $NBUD.ca – Amid #coronavirus, Canadian #cannabis stores see ‘unprecedented’ sales surge $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 1:40 PM on Tuesday, March 17th, 2020

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. The company recently received Canadian Cultivation Licence for its Quebec Facility. Learn More.

Amid coronavirus, Canadian cannabis stores see ‘unprecedented’ sales surge

By Matt Lamers

  • Cannabis stores in Ontario and Alberta reported “unprecedented demand” as the country hunkers down to fight a worsening coronavirus outbreak, industry sources say

Executives told Marijuana Business Daily there is no threat to supply chains at this time, and safety measures have been put into place for employees and consumers.

Spiritleaf CEO Darren Bondar said his 46 stores “experienced an unprecedented demand for cannabis over the weekend with sales up 20% over the previous one and a record number of customers served.

“The supply chain remains in place, stores are stocked and we have seen an uptick in edible purchases.”

Spiritleaf is encouraging online ordering via click-and-collect programs in British Columbia, Alberta and Ontario.

In most of Canada, provinces retain monopolies over cannabis e-commerce with delivery. The click-and-collect program allows privately owned stores to take payment online so customers can pick up their orders in stores.

Ontario up 80%

Sales surged week-over-week at Ontario’s monopoly online cannabis store, but some of that increased demand is attributable to lower prices.

The government-owned store aggressively dropped prices on some products as part of an ongoing drive to improve competitiveness.

Mike Ravkine, who operates the popular price-tracking and inventory tool WhatsMyPot, recorded significant price drops at the Ontario Cannabis Store.

“The last three days have seen a marked increase in volume in sales on OCS.ca and a high demand for our same day/next day delivery option where it is available,” Daffyd Roderick, OCS communications director, wrote in an email to Marijuana Business Daily.

“Some authorized retail stores are also reporting an increase in customer volume. Saturday saw almost 3,000 orders, an 80% increase over an average Saturday.”

The OCS’ 4,000 orders Sunday represent a 100% increase from the previous week, officials told MJBizDaily.

Roderick said the OCS has sufficient inventory to meet demand.

“We are working closely with our partners and currently delivering and receiving as per our normal schedule,” he said.

Physical stores in Ontario are also seeing an increase in orders, noted Sessions Cannabis CEO Steven Fry.

“Not unlike major grocery retailers, Sessions Cannabis has seen a significant increase in sales this week due to growing concerns regarding COVID-19 social distancing protocols,” he wrote in an email.

Compared to the previous week, Fry said the Sessions on the Beach location in Toronto saw approximately:

  • A 10% more transactions per day.
  • A 10% increase in dollars spent per transaction.
  • A 21% overall sales growth.

B.C. ‘steady’

British Columbia’s online monopoly BC Cannabis Stores has not seen any new sales trends.

A spokesperson for the BC Liquor Distribution Branch (BCLDB), which operates the store as well as the province’s cannabis wholesale system, said there has been no change in sales online.

The BCLDB spokesperson also said sales on the wholesale side remain “very flat, steady.”

Alberta Cannabis, the only legal online store in the province, said it is not sharing any information.

Quebec bump

Quebec’s monopoly online store also saw increased sales.

Société québécoise du cannabis (SQDC), which is also the wholesaler for the province, said its website remains “fully functional and parcels are still being delivered.”

“Indeed, we have seen an increase in sales over the last days,” spokesman Fabrice Giguere wrote in an email to MJBizDaily.

Giguere said inventory levels, both online and in stores, are stable.

“We invite all customers returning from a trip abroad or who experience flu-like symptoms to do their shopping directly online,” he noted.

Safety first

Physical cannabis stores are taking measures to increase the health and safety of customers and employees to support social distancing.

“Sessions Cannabis is taking extra measures to ensure the safety of our customers and staff through increased cleaning and sanitation measures and we will continue to monitor the situation to ensure a safe shopping experience,” Fry said.

Bondar said Spiritleaf continues to follow all advice and government guidelines.

“All surfaces, door handles and employee stations are being sanitized throughout the workday to maintain a clean, safe environment for all of us,” he said.

“We encourage customers to check on store hours in the event that they may change to accommodate various staff members’ needs to take care of family members or who are returning from vacation and in self-isolation, which has been happening at a few locations across the country.

Source: https://mjbizdaily.com/amid-coronavirus-canadian-cannabis-stores-see-unprecedented-sales-surge/

AGORACOM Welcomes New Age Metals $NAM.ca A North American Leader in PGM and Lithium Exploration- River Valley #PGM Project hosts 2.9Moz #Palladium Equivalent (Measured & Indicated) $WG.ca $XTM.ca $WM.ca $PDL.ca $GLEN

Posted by AGORACOM-JC at 9:50 AM on Tuesday, March 17th, 2020

(NAM:TSXV)


A Green Metals Company

  • New Age Metals has two divisions which focus on the exploration and development of green metals: Platinum Group Metals and Lithium

i.) PGM Division: focus on development of the 100% owned River Valley PGM Project.

ii.) Lithium Canada: focus on exploration of hard rock lithium, in Manitoba, Canada.

  • Eric Sprott is a strategic shareholder and has an 18.56% ownership of the Company’s current issued and outstanding shares on a post conversion beneficial ownership basis

PGM DIVISION – River Valley PGM Project near Sudbury, ON

  • Largest 100% owned undeveloped primary PGM project in North America, Palladium is the main payable metal accounting for 65% of revenue stream based on 2019 PEA.
  • 1:0.4 (Pd:Pt).
  • Excellent infrastructure and within 100 kilometers of the Sudbury Metallurgical Complex.
  • NI 43-101 Mineral Resource Estimation Q1 2019.
  • PEA Q3 2019.
  • 2020 plan to follow up on PEA recommendations.

Preliminary Economic Assessment demonstrates positive economics for a large-scale open pit mining operation.

PEA Highlights (CDN$):

  • Life of mine (LOM) of 14 years, with 6 million tonnes annually of potential process plant feed at an average grade of 0.88 g/t Palladium Equivalent (PdEq) and process recovery rate of 80%, resulting in an annual average payable PdEq production of 119,000 ounces.
  • Pre-Production capital requirements: $495 M.
  • Undiscounted cash flow before income and mining taxes of $586M.
  • Undiscounted cash flow after income and mining taxes of $384M.
  • Average unit operating cost of $19.50/tonne over the life-of-mine.
  • Potential for up to 325 jobs at the peak of production.
  • Using March 11, 2020 spot Palladium price (US$2,275/oz) River Valley Project After-tax IRR is 30% and After-tax NPV (5%) is $C858M.
Map-nam-1

Figure 1: River Valley Project site map including results from the 2019 Mineral Resource Estimate by zone.2020 River Valley Project Exploration & Development Plan

Management has developed a three-phase exploration and development plan for the balance of 2020. 

  • Phase One will focus on drilling to expand the boundaries of the Pine Zone discovery and to generate rhodium data for future mineral resource estimations.
  • Phase Two will involve drill testing further geophysical targets in the Northern area of the project, identified in the 2017/2018 induced polarization surveys. The target areas to be drill tested in this program are outlined in Figure 1.
  • Finally, Phase 3 will be focused on metallurgy – with the primary objective being to improve process recoveries of platinum metals, particularly palladium and including rhodium. We plan to start Phase 1 in early Q2-2020.
  • Note that each phase is contingent on success from the previous phase.
nam-map-2

PGM DIVISION – Genesis PGM-Cu-Ni Project in Alaska

On April 18, 2018 New Age Metals acquired the Genesis Platinum Group Metals Project.

nam-map-4

Figure 3: Genesis Project location map. The road accessible Genesis PGM-Cu-Ni Project adjacent to Richardson Highway and 138 kv electric lines. The project is 460 road kilometers to Fairbanks, Alaska and 120 road kilometers to the all-weather port city of Valdez

  • The Genesis project’s PGM-Cu-Ni mineralization is hosted in the Tonsina mafic-ultramafic complex, an undrilled, virtually unexplored layered mafic-ultramafic complex. Recent petrology indicates the Genesis mineralization is similar to the Stillwater and Great Dyke complexes.
  • Known PGM mineralization covers a distance of 9 km across the prospect.
  • The Genesis PGM-Cu-Ni Project is an under explored, highly prospective multi-prospect drill ready property that warrants follow-up drilling, additional surface mapping, sampling to expand the known footprint of mineralization and to determine the ultimate size and grade of the layered mineralization outlined to date.
  • The stable land status, ease of access and superb infrastructure make this project prospective for year-around exploration, development and production.
  • Summer 2019 exploration efforts doubled the strike length of prospective mineralization at our road accessible Genesis PGM-Ni-Cu Project in Alaska.
  • Currently, New Age is seeking an Option/Joint Venture Partner to assist in the exploration and development of this project.
  • Drill ready PGM-Ni-Cu reef style target with 2.4 grams/ton Palladium (Pd), 2.4 grams/ton Platinum (Pt), 0.96% Nickel (Ni), and 0.58% Copper (Cu).
  • Reef mineralization is open to the west, east, north, and at depth
  • Mineralized reef identified in outcrop for 2000 m along strike and a 40 m true thickness
  • Separate style of chromite mineralization contains Platinum Group Metals (PGM) up to 2.5 g/t Pd and 2.8 g/t Pt.
  • No historic drilling has been done on the project.
  • Project is within 3 km of a paved highway and electric transmission line.

Lithium Division

New Age Metals is the largest mineral claim holder in the prolific, Winnipeg River – Cat Lake Pegmatite Field. All of the claims are held by Lithium Canada Development, a 100% owned Lithium Division of New Age Metals. The company presently has eight Lithium Projects in the region which are along strike of the Tanco Pegmatite and the claims encompass several pegmatite groups. 

Situated around the Tanco Mine which in 2019 was acquired by Chinese miner Sinomine, the projects are located 140 kilometres northeast of Winnipeg, Manitoba.

  • Three of the projects are considered drill ready. Lithium One, Lithium Two and Lithman West
  • Active exploration of the claim holdings is ongoing.
  • New Age Metals has signed an exploration agreement with the Sagkeeng First Nation in regards to the exploration and development of any of the company’s claims that are located on traditional Sagkeeng territories.
  • The Tanco Mine was one of North America’s only producers of Tantalum, Cesium and Lithium minerals (Spodumene), with the mine opening in 1969. Owned by the Cabot Corporation as of 1993 until 2019, when Chinese miner Sinomine purchased from Cabot for US$130M.
  • Presently the Tanco Mine produces Cesium Formate, a completion fluid for the petroleum industry.
  • Management is actively seeking a qualified and dedicated Option Joint Venture Partner to assist in the exploration and development of these highly prospective projects.
Lithium-Projects-locations-1
map-nam-5

Synthetic media: The real trouble with #deepfakes – SPONSOR: Datametrex AI Limited $DM.ca

Posted by AGORACOM-JC at 5:22 PM on Monday, March 16th, 2020

SPONSOR: Datametrex AI Limited (TSX-V: DM) A revenue generating small cap A.I. company that NATO and Canadian Defence are using to fight fake news & social media threats. The company announced three $1M contacts in Q3-2019. Click here for more info.

Synthetic media: The real trouble with deepfakes

By M. Mitchell Waldrop

  • The snapshots above look like people you’d know. Your daughter’s best friend from college, maybe? That guy from human resources at work? The emergency-room doctor who took care of your sprained ankle? One of the kids from down the street?
  • “Deepfakes play to our weaknesses,” explains Jennifer Kavanagh, a political scientist at the RAND Corporation and coauthor of “Truth Decay,”

Nope. All of these images are “deepfakes” — the nickname for computer-generated, photorealistic media created via cutting-edge artificial intelligence technology. They are just one example of what this fast-evolving method can do. (You could create synthetic images yourself at ThisPersonDoesNotExist.com.) Hobbyists, for example, have used the same AI techniques to populate YouTube with a host of startlingly lifelike video spoofs — the kind that show real people such as Barack Obama or Vladimir Putin doing or saying goofy things they never did or said, or that revise famous movie scenes to give actors like Amy Adams or Sharon Stone the face of Nicolas Cage. All the hobbyists need is a PC with a high-end graphics chip, and maybe 48 hours of processing time.

It’s good fun, not to mention jaw-droppingly impressive. And coming down the line are some equally remarkable applications that could make quick work out of once-painstaking tasks: filling in gaps and scratches in damaged images or video; turning satellite photos into maps; creating realistic streetscape videos to train autonomous vehicles; giving a natural-sounding voice to those who have lost their own; turning Hollywood actors into their older or younger selves; and much more.

Deepfake artificial-intelligence methods can map the face of, say, actor Nicolas Cage onto anyone else — in this case, actor Amy Adams in the film Man of Steel.

Yet this technology has an obvious — and potentially enormous — dark side. Witness the many denunciations of deepfakes as a menace, Facebook’s decision in January to ban (some) deepfakes outright and Twitter’s announcement a month later that it would follow suit.

“Deepfakes play to our weaknesses,” explains Jennifer Kavanagh, a political scientist at the RAND Corporation and coauthor of “Truth Decay,” a 2018 RAND report about the diminishing role of facts and data in public discourse. When we see a doctored video that looks utterly real, she says, “it’s really hard for our brains to disentangle whether that’s true or false.” And the internet being what it is, there are any number of online scammers, partisan zealots, state-sponsored hackers and other bad actors eager to take advantage of that fact.

“The threat here is not, ‘Oh, we have fake content!’” says Hany Farid, a computer scientist at the University of California, Berkeley, and author of an overview of image forensics in the 2019 Annual Review of Vision Science. Media manipulation has been around forever. “The threat is the democratization of Hollywood-style technology that can create really compelling fake content.” It’s photorealism that requires no skill or effort, he says, coupled with a social-media ecosystem that can spread that content around the world with a mouse click.

Source: https://www.knowablemagazine.org/article/technology/2020/synthetic-media-real-trouble-deepfakes

Can #coronavirus do for #edtech what demonetisation did for digital payments in India? – SPONSOR: BetterU Education Corp. $BTRU.ca $ARCL $CPLA $BPI $FC.ca

Posted by AGORACOM-JC at 4:43 PM on Monday, March 16th, 2020
SPONSOR:  BetterU Education Corp. aims to provide access to quality education from around the world. The company plans to bridge the prevailing gap in the education and job industry and enhance the lives of its prospective learners by developing an integrated ecosystem. Click here for more information.

Can coronavirus do for edtech what demonetisation did for digital payments in India?

  • The Covid-19 pandemic has forced several schools and colleges across India to temporarily close. In Delhi alone, over two million kids are being forced to stay at home with primary schools shut until March 31.
  • With fresh cases being reported each day, there are expectations that more schools and colleges will be closed in the coming weeks.

By Ananya Bhattacharya

On Nov. 8, 2016, digital payments companies became mainstream in India overnight after the government suddenly decided to demonetise two high-value currency notes. Now, education technology (edtech) firms are hoping for an encore in the wake of the coronavirus outbreak.

The Covid-19 pandemic has forced several schools and colleges across India to temporarily close. In Delhi alone, over two million kids are being forced to stay at home with primary schools shut until March 31. With fresh cases being reported each day, there are expectations that more schools and colleges will be closed in the coming weeks.

Edtech companies are jumping to make the most of the situation, offering free access to their courses during a time that typically flags off the exam season.

But overnight success might be hard to come for these platforms, experts said.

“While a smartphone is good enough for browsing, social media, and so on, for studies, assignments, and projects, it doesn’t suffice,” Prateek Shukla, CEO & co-founder Bengaluru-based coding bootcamp Masai School, told Quartz. “A stable internet and electricity connection is the biggest challenge.” Power outages are still very frequent across most Indian cities, especially in smaller towns.

And that is just one of the many hurdles. Companies, though, are going all out to make hay.

Wooing India

On March 11, Bengaluru-based Byju’s, the world’s biggest edtech firm, said it was making all its learning programmes for students in classes 1 through 12 free until April-end. Soon after, rival Toppr offered free access to its live and video classes for school kids until March 31, and Unacademy announced 20,000 free live classes for candidates looking to prep for entrance exams for union public service commission, banking, railways, and more.

“We want learners to utilise this time…We will support the education system in every way possible to weather the storm,” said Gaurav Munjal, co-founder and CEO of Unacademy. Toppr said it will consider extending the free access for students if schools don’t reopen after March.

Edtech is already well equipped to handle a possible surge in demand, said Akash Singhal, founder & CEO of edtech startup Illumnus. Teachers producing online lessons have already been working remotely, so there is no additional cost in producing lessons.

The initiatives are already bringing in gains.

Noida-based Gradeup has seen a 25% uptick in daily enrolments since it doubled the number of free video on its platform in light of the coronavirus outbreak.

Source: https://qz.com/india/1817115/byjus-toppr-unacademy-ready-for-coronavirus-pandemic/

INTERVIEW: Datametrex $DM- The Small Cap #AI Company That NATO And Canadian Defence Are Using To Fight Fake News & Social Media Threats

Posted by AGORACOM-JC at 7:00 PM on Sunday, March 15th, 2020

Until now, investor participation in Artificial Intelligence has been the domain of mega companies and those funded by Silicon Valley.  Small cap investors can finally consider participating in the great future of A.I. through Datametrex AI (DM: TSXV) (Soon To Be Nexaology) who has achieved the following over the past few months:

  • Q3 Revenues Of $1.6 million,  an increase of 186%
  • 9 Month Revenues Of $2.56M an increase of 37%
  • Repeat Contracts Of $1M and $600,000 With Korean Giant LOTTE   
  • $954,000 Contract With Canadian Department of Defence To Fight Social Media Election Meddling
  • Participation In NATO Research Task Group On Social Media Threat Detection 

When a small cap Artificial Intelligence company is successfully deploying its technology with military and conglomerates, smart investors have to take a closer look.   That look can begin with our latest interview of Datametrex CEO, Marshall Gunter, who talks to us about the use of the Company’s Artificial Intelligence to discover and eliminate US Presidential election meddling.  The fake news isn’t just targeting candidates specifically, it also targets wedge issues such as abortion cases now before the US Supreme Court and even the Coronavirus.   Watch this interview on one of your favourite screens or hit play and listen to the audio as you drive. 

Mota Ventures $MOTA.ca Announces 832% Growth in February 2020 over the Same Period Last Year and Provides Update on First Class CBD Sales $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 5:33 PM on Friday, March 13th, 2020
http://www.smallcapepicenter.com/Mota%20Square%20Logo%20For%20Blog.jpg

VANCOUVER, BC / March 13, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC:PEMTF) (the “Company“) is excited to announce that for the month of February 2020, its First Class CBD brand achieved sales of Cdn$2,981,000, with related expenses for the same time period totaling Cdn$2,814,000. Due to accelerated marketing efforts in late January 2020, the brand was able to improve gross margins by 4.9% from January 2020 to February 2020. The Company anticipates these efforts will yield a further positive impact on revenue and margin in subsequent months. Sales for February 2019 were Cdn$320,000; therefore, February 2020 represents an increase of 832% over the same period last year.

First Class offers a CBD hemp-oil formulation intended to provide users with the therapeutic benefits that hemp may offer. The hemp oil used in the products is derived from hemp grown and cultivated in the United States. The extraction process is designed to maintain all the beneficial qualities that hemp may offer. First Class offers a range of products, which include CBD oil drops, CBD gummies, CBD pain relief cream, CBD skin serum and CBD coffee. The Company plans to continue growth of First Class in the United States over the balance of 2020, as well as an expansion into the European market.

“I am extremely pleased with the performance of the First Class brand through the beginning months of 2020. The continued growth we are experiencing is evidence of the strong consumer demand in the CBD market. While eCommerce demand is generally weakest in January and February, we continue to demonstrate our leadership through achieving approximately Cdn$5,874,000 in revenue through the first two months of the year,” stated Ryan Hoggan, CEO of the Company.

The Company cautions that figures for revenue, expenses and margin generated from the sale of First Class CBD products have not been audited, and are based on calculations prepared by management. Actual results may differ from those reported in this release once these figures have been audited. These figures were translated from US dollar into Canadian dollar using the Bank of Canada monthly average exchange rates of 1.3301 for January 2019, 1.3206 for February 2019, 1.3087 for January 2020 and 1.3286 for February 2020.

About Mota Ventures Corp.

Mota Ventures is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value added products from its Latin American operations and distribute it both domestically and internationally. Mota has established distribution networks through the acquisition of First Class CBD in the United States and Sativida in Europe. Mota Ventures is also seeking to acquire revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Empower Clinics $CBDT.ca – #Cannabis Won’t Cure #Coronavirus, but It Can Help Ease Certain Flu Symptoms $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 5:00 PM on Friday, March 13th, 2020

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics.
  • Patient database of over 165,000 patients 
  • Platform generating $1.4M USD (9 months ending Sept. 30, 2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Recently launched CBD extraction facility
  • First extraction system capacity = 2,300 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025
  • Company to Create Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network

Cannabis Won’t Cure Coronavirus, but It Can Help Ease Certain Flu Symptoms

By Brianna Wheeler |

During a normal flu season, frequent weed smokers know the drill.

Pay closer attention to everyone’s cough patterns during a smoke sesh. Stop accepting mouth-wet blunts from strangers. And if you think you’re coming down with something, wave a lighter under the mouthpiece before passing the pipe.

This year, obviously, things are a bit more serious. We’re dealing with multiple citywide quarantines, global economic disruption, and a pandemic being compared to the damn Spanish flu. It’s enough to make self-respecting cannabis enthusiasts re-evaluate their medicine cabinet and diversify their stash box.

Obviously, there’s no dependable research on CBD’s or THC’s effect on COVID-19. But we do know a few things about cannabis and general wellness. Down the rabbit hole of alternative cannabinoids and non-psychoactive cannabis, there is a wealth of potential medicinal benefits both preventative and curative.

At least when it comes to the regular flu, CBD has been found to help support immune systems, ease symptoms, and replace over-the-counter pain relievers, sleep aids, and medicated salves currently taking up space in our medicine cabinet. But not just any CBD will do, and CBD alone won’t do it all.

Obviously, the best course of action right now is to keep vigorously washing your hands, mind your coughs, avoid large crowds, and be a bit more stingy with your pipes and joints. But if you find yourself slipping under the weather, for whatever reason, here are a few things to know about how cannabis might help ease symptoms.

CBD for Immune System Support

Tons more research is required to accurately map the relationship between the immune and endocannabinoid systems, but it’s well established that CBD helps reduce self-harming autoimmune and inflammatory responses. “CBD has been found to act as an immune system modulator,” says Anna Symonds, director of East Fork Cultivars’ CBD Certified program. “This means that it’s like a thermostat—it can turn the level of activity down or up, depending on the body’s needs.”

Source: https://www.wweek.com/potlander/2020/03/10/cannabis-wont-cure-coronavirus-but-it-can-help-ease-certain-flu-symptoms/

#Coronavirus Scare Gives #Telehealth an Opening to Redefine Healthcare #Mhealth SPONSOR: CardioComm Solutions $EKG.ca – $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 6:12 PM on Thursday, March 12th, 2020

SPONSOR: CardioComm Solutions (EKG: TSX-V) – The heartbeat of cardiovascular medicine and telemedicine. Patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment.

Coronavirus Scare Gives Telehealth an Opening to Redefine Healthcare

With the coronavirus threatening to become a pandemic, health systems and telehealth vendors see this as an opportunity to bring connected health to the forefront – and reshape the future of healthcare.

By Eric Wicklund

March 05, 2020 – As Congress votes on a funding package that includes Medicare waivers for some telehealth services and the Health Information and Management Systems Society (HIMSS) cancels its conference in Florida, healthcare providers across the country are looking at how connected care programs can be used to handle the coronavirus – also called COVID-19 – threat.

Most see the exercise as an extension of their preparations for flu season. Some see this as an opportunity to lobby for telehealth adoption across the board, saying a possible epidemic offers ample evidence of the value of telehealth and mHealth.

Defining Telehealth’s Value in a Changing Landscape

“COVID-19 is different because we do not know all the factors surrounding transmission and its effects on patients,” Jason Hallock, Chief Medical Officer for SOC Telemed, points out. â€œBecause coronavirus is new and there have been a significant number of deaths, the uncertainty surrounding that is scaring both patients and the general public. Our healthcare workers do not have all the answers yet. Telehealth providers are challenged to make recommendations when there are still many unknowns. Telemedicine can be useful to evaluate and reassure patients in alternative settings, and also can be used to help patients decide who needs to be seen in the hospital or an alternative setting like an urgent care.”

Hallock says telehealth can help by enabling healthcare providers to treat isolated patients, thus preventing the spread of what has so far been an extremely contagious virus.

In a Q&A with mHealthIntelligence, Peter Antall, MD, President and Chief Medical Officer for American Well, offered an in-depth take on how telehealth might be used.

READ MORE: Scripps Researchers Use mHealth Wearables to Track Flu Outbreaks

Q. Telehealth has long been seen as an ideal means of expediting care during flu outbreaks. How is the coronavirus scare different? Does this pose any unique challenges that telehealth can address?

A. The novel coronavirus, or COVID-19, is similar to influenza in how it is transmitted (airborne), how symptoms manifest themselves, and the fear it stirs among those individuals at risk. When evaluating patients through telehealth, we use similar methodology as that used for influenza, except that the current Centers for Disease Control and Prevention (CDC) recommendations call for risk stratification based on known exposure or travel to endemic areas and referral for testing for those at high risk or those who are sick enough to need hospital care. Also, unlike with influenza, there are no current specific treatments, like antivirals, for the coronavirus at this time. 

If local person-to-person spread expands to wide community spread, we expect care will need to evolve to a method that is quite similar to how we treat influenza today. Under those circumstances, we will likely begin diagnosing coronavirus-like illness (CLI) on a clinical basis, without testing. We would likely then only be expected to refer inpatients with CLI who need hospital care clinically, while those with milder symptoms will likely be treated and monitored at home so as to limit the spread of this disease and not overwhelm our healthcare facilities.

In this way, telehealth is an ideal venue for an outbreak like this. We can increase access to care. We can offer care that is commensurate with the acuity and nature of the symptoms and make referrals as needed. This helps with infection prevention and control and also allows patients to receive their care in the home without exposing themselves to further illness.

One other notable point is the potential for telehealth to help in providing routine care for other conditions and offset coronavirus fears in the . Patients have other healthcare needs unrelated to coronavirus, but many are afraid to go to healthcare settings for fear of catching disease. This has begun to result in a migration of patients to telehealth. For example, on February 25, we saw telehealth urgent care patient volume that was 11 percent higher than expected. Many patients are now sharing anecdotes indicating they were afraid to sit in a waiting room, so they used telehealth instead.

READ MORE: Using Telehealth Technology for Care Coordination During a Disaster

Q. Are there new tools or technologies available that can be useful in dealing with the coronavirus?

A. Telehealth itself is a tool in this fight. Keep in mind that there are many varieties of telehealth. It can be used to connect a doctor or other provider with a patient in the home via smartphones or tablets. It can also be used for provider (specialist)-to-provider consultations in remote areas, for example. Telehealth carts also exist in healthcare settings and can be used not only to import care, but also to limit healthcare workers’ exposure to the virus by using a cart in the isolation room.  We see patients primarily through live video interactions, but we also can fall back to informed telephone calls, synchronous chatting for therapy and asynchronous secure messaging for ongoing communications.

The use of symptom trackers and chatbots is another promising area for coronavirus response. These technologies allow algorithms to be created and adjusted as more is learned about the coronavirus. These bots interact with patients and can perform assessments, triage and ongoing support. The bots can even escalate an interaction to a telehealth encounter or refer the patient for in-person care.

Finally, home monitoring and medical tricorders are another promising approach to care. Traditional remote patient monitoring has established value for managing certain chronic conditions, but the next wave of home monitoring includes consumer devices like smartwatches (like the Apple Heart Study), home TVs, and home medical tricorders like Tytocare that can perform a remote examination. These tools aid clinicians and patients and provide more robust health data conveniently from the home setting. Providers can also use the data generated to better care for the patient or regularly monitor certain conditions.

Q. What must care providers know about telehealth before using it to deal with the coronavirus?

READ MORE: HHS Is Looking For mHealth Devices That Can Diagnose Influenza

A. Providers must know and understand their role in this or any other healthcare crisis. They should be well informed and trained to follow current CDC or World Health Organization guidelines. They should also understand that telehealth is a powerful tool for helping fight this outbreak. And they should know that telehealth is a safe way to treat and/or triage these patients. Whether the provider is a primary telehealth provider or is not using telehealth today, there is a real opportunity to participate and play a role in the response. 

Providers who have a brick-and-mortar practice should be encouraged to use telehealth as a triage tool. Providers also need to understand that during this time, patients with other non-respiratory conditions also need care. These patients should be afforded a safe way to access care without risk of infection. Telehealth is also a tool to aid in this process, as some patients are fearful of going to healthcare facilities right now. The office-based provider can likewise process other patients by practicing this way.

Q. What are the barriers or challenges associated with using telehealth to deal with the coronavirus scare?

A. Telehealth visits are typically sufficient to complete a robust initial assessment. This allow the provider to assign a risk category, make other diagnoses, or deem the patient as “worried well.” Some patients may require additional care, as most telehealth in the home lacks certain medical peripherals that might be needed. Other reasons for referral would include a high-risk patient who needs to be tested or a patient who requires escalation of care due to the severity of their illness. Telehealth visits are generally sufficient for screening patients, assigning a risk category, answering questions and recommending the next steps a patient should take.

The barriers to telehealth—such as instances when the patient and provider do not yet have a relationship—are easily overcome providers receive similar training around the use of telehealth and as longitudinal patient records become more available to guide care. Occasionally the lack of medical peripherals or the inability to touch the patient during an exam is a barrier, as some patients need hands on care (e.g., IV, procedures). We have policies that mitigate these problems in most cases. However, on occasion, a telehealth patient must be referred for in-person evaluation.

Q. Is there anything that the CDC or any other government agency can do to support telehealth adoption to deal with the coronavirus? 

A. It is useful for the CDC (and the WHO) to highlight the important role of telehealth in this outbreak because it certifies our role within the broader medical community and raises awareness about this tool.

It would be helpful if the CDC were to make specific recommendations to telehealth providers that relate to telehealth evaluation of the coronavirus and associated referrals, coding and monitoring. It would also be helpful if the CDC were to play a role in advocacy efforts focused on government reimbursement, particularly in this emergency situation. Efforts to increase consumer awareness about telehealth as a safe option for care also could prove essential. When this outbreak settles down, we would encourage the CDC and HHS to collaborate around coronavirus standards of care and preparedness so that patients can expect telehealth providers to be ideally prepared and well-coordinated for the next outbreak and so that we can offer high-quality care in this manner to all Americans.

We also believe that our public health system would benefit greatly from owning its own telehealth network infrastructure. This would allow the CDC to better scale up, solve for geography and improve surveillance. It would even allow its public health workers to use technology to monitor patients under quarantine in the home, saving themselves travel and limiting healthcare workers’ exposure.

Q.  What more can be done with telehealth in the future to plan for these types of outbreaks, or to perhaps address them before they become serious?

A. Much needs to be done throughout our country to better prepare. We need permanent leaders placed at the U.S. Department of Health and Human Services, the National Institutes for Health, the US Department of Homeland Security and other key areas, and we need to reinstate a pandemic-preparedness role at the National Security Council. We need to fund international efforts to improve screening and research for emerging diseases, and we need surveillance programs and good international coordination. We need to fund (not decrease funding) for our frontline groups, like the CDC, HHS and local public health services. These are our fighters, and we need them ready and funded properly as an outbreak like this is a national security issue. We need stockpiles of materials. Finally, we should be partnering with the pharmaceutical industry on affordable medications and vaccine research.

Our national telehealth operation today acts like an emergency alert system. We see cases or potential cases before they are reported. At American Well, our influenza activity indicator map is more accurate and more timely than that of the CDC. We already play a meaningful role in many disease states, including outbreaks. There are still many adoption and awareness challenges that exist when it comes to telehealth. Hopefully this unfortunate event will help consumers, providers and others start to more clearly see how they can and should use telehealth for future healthcare needs.

Another barrier that we continue to work on is that of reimbursement. Telehealth is a cost-effective way of receiving care, but it is still not always a covered benefit by insurance. Most commercial plans are reimbursing and there is increasing adoption in Medicare Advantage and Medicaid managed care. But there are still gaps, including a big gap in fee-for-service coverage for Medicare coverage in the home. Efforts at reform are underway (see the CONNECT Act), but more work needs to be done so that all Americans can take advantage of this amazing service.

Additionally, with coordination being so important during outbreaks like this, the simple step of integrating telehealth with other health information systems, such as EHRs or clinical-decision support, can make care more seamless and foster better care coordination. This would speed up access to critical care. Case in point: Consider a scenario where a patient consults with a physician over a telehealth network and displays symptoms of COVID-19 while presenting one or more correlating risk factors. The physician could easily document the experience, dispatch an alert to a local ED, and ensure precautions are taken by medical staff to usher this patient into a contained room or unit to begin testing and treatment. We’re working to ensure this type of communication is happening at all levels, but there’s still much room for improvement on this front. 

Health System Execs Respond to the Threat

In an op-ed prepared for the Alliance for Connected Care, Todd J. Vento, MD, MPH, Intermountain Healthcare’s Medical Director of Infectious Diseases Telehealth Service; Ethan Booker, MD, Medical Director of MedStar’s Telehealth Innovation Center; and Lawrence “Rusty” Hofmann, MD, Stanford Health’s Medical Director of Digital Health, made their pitch for telehealth:

“Telehealth, which has proven to be a very useful tool in addressing patient needs during flu season, will improve our collective ability to address COVID-19 if it hits on a larger scale. Telehealth offers several advantages over in-person care in the event of a pandemic.

One key advantage of telehealth is speed,” the three wrote. “Patients can access clinicians 24/7 without an appointment or physical trip to the doctor. Using telehealth, our providers in the Stanford Primary Care team, MedStar Health and Intermountain Healthcare have been actively evaluating and treating patients with influenza.  Current providers at Stanford Health estimate that almost 50% of patients are getting oseltamivir (Tamiflu).  Because there is no current, specific medication for Coronavirus, we must be able to advise patients of reasonable self-directed treatment and surveillance to keep them home. 

Keeping patients at home is a significant advantage of telehealth. In-home video visits limit community exposure by allowing patients to avoid contact with other patients in waiting rooms and direct contact with providers during the exam.  Our health systems have providers who are equipped to work from their own homes, significantly increasing the safety of providers and bolstering the workforce to respond to crisis.  Workforce readiness in a crisis that may include such dramatic measures as school and day care closures is a significant concern for health systems which may be strained to respond.  Health systems are also using telehealth to continue surveillance of patients already identified as at risk while keeping them at home.

Next, telehealth ensures that treatment in brick-and-mortar settings is reserved for high-need patients.  Moreover, with patients being seen in their own homes, providers and health systems will be able to triage and screen exponentially more patients with telehealth vs. an in-person visit.

Finally, telehealth allows patients who do not have access to infectious diseases (ID) specialists to access this specialized care from the small number of experts across the country. When Intermountain first offered ID telehealth consultation to rural systems throughout the west, one provider fielded 1,000 consultation requests in the first fifteen months. To date, the service has provided telehealth care to over 4,700 patients, 50 percent of whom are over 65 years old.

Each of these advantages illustrate how telehealth can thwart the spread of COVID-19 and stop it from overwhelming our already stretched medical system.”

The three health executive also urged lawmakers to take action to reduce barriers to telehealth that have kept adoption low:

“Congress must act to ensure that seniors – a particularly vulnerable population generally and for this virus in particular – are able to receive necessary triage and care through telehealth. 

Today, there are restrictions in Medicare that prevent providers outside of very rural areas from being paid for care provided through telehealth. As a result, many providers do not offer telehealth services to seniors. The lack of reimbursement creates a perverse incentive of encouraging patients to come for in-person care, which will only overwhelm our health system as well as augment the virus’s spread.

Congress must give the Secretary of Health and Human Services the ability to waive these restrictions in times of public health emergencies. As part of the bipartisan, bicameral CONNECT for Health Act, telehealth champions in Congress foresaw this need and drafted a provision that would give the Secretary the ability to waive telehealth restrictions just as he/she would waive Conditions of Participation, Stark Laws licensure, or other requirements when public health emergencies are declared.”

Source: https://mhealthintelligence.com/news/coronavirus-scare-gives-telehealth-an-opening-to-redefine-healthcare

#Edtech firms offer free access to colleges that is impacted by #Coronavirus – SPONSOR: BetterU Education Corp. $BTRU.ca $ARCL $CPLA $BPI $FC.ca

Posted by AGORACOM-JC at 5:12 PM on Thursday, March 12th, 2020
SPONSOR:  BetterU Education Corp. aims to provide access to quality education from around the world. The company plans to bridge the prevailing gap in the education and job industry and enhance the lives of its prospective learners by developing an integrated ecosystem. Click here for more information.

Edtech firms offer free access to colleges that is impacted by Coronavirus

Beginning Thursday, online learning giant Coursera said it is going to provide every impacted university in the world free access to its course catalogue through ‘Coursera for Campus’ until July 31

  • Beginning Thursday, online learning giant Coursera said it is going to provide every impacted university in the world free access to its course catalogue through ‘Coursera for Campus’ until July 31.

By: Neha Alawadhi & Samreen Ahmad

Online education companies in India and globally are offering their paid programmmes to students — whether in school or pursuing higher education — free of cost because of the COVID-19 pandemic.

Beginning Thursday, online learning giant Coursera said it is going to provide every impacted university in the world free access to its course catalogue through ‘Coursera for Campus’ until July 31.

“We’re going to make ‘Coursera for Campus’ offering freely available to any college or university in the world that is impacted by coronavirus, in the hope that they can rapidly allow students to start learning and ensure we have minimal impact from coronavirus on the student community,” said Leah Belsky, chief enterprise officer and senior vice-president, Coursera.

Coursera, founded by Stanford Professors Andrew Ng and Daphne Koller, has 48 million registered learners worldwide and offers courses, specialisations, degrees, and certificate programmes online.

The ‘Coursera for Campus’ offers job-relevant online education to students, alumni, faculty, and employees of firms like Mindtree, Tata Communications, Axis Bank, Infosys, Airtel, and Manipal Group.

Indian universities can continue teaching their students online without creating new infrastructure. Coursera’s existing ‘Coursera for Campus’ partners include Manipal Academy of Higher Education, UPES, Shiv Nadar University, KL University, NMIMS, and Pearl Academy.

In India, it has 5 million registered learners, and is adding over 100,000 learners per month.

Universities can sign up to provide their enrolled students with access to more than 3,800 courses and 400 specialisations from Coursera’s top university and industry partners.

Similarly, Indian education technology firms are also offering free classes and course material for students impacted by the novel coronavirus. On Wednesday, the World Health Organization declared COVID-19 a global pandemic.

Edtech firm Byju’s also said it will provide free access to its complete app to school students till the end of April.

Some Indian states like Kerala, Karnataka and New Delhi have already announced the closure of schools.

A UNESCO report states that the education of over 290 million students across 13 countries will be interrupted because of the COVID-19 pandemic.

Another edtech platform Unacademy said it will conduct close to 20,000 free live classes on its platform, across exam categories like UPSC, banking, railways and so on.

Unacademy claims it has 10,000 educators, 13 million learners, and subscriptions for over 30 exam categories.

Educational Initiatives, a 20-year old edtech company based out of Bengaluru is also offering 60 days free access of Mindspark to all students, so that the school closure due to COVID-19 does not impact their learning.

Mindspark is an artificial intelligence-powered specialised mathematics programme developed for children’s learning.

Similarly, edtech firm Toppr is going to provide free live classes to students in classes 5 to 12.

While it is yet to be seen how effective these measures will be, Coursera’s Belsky said the US education system invested in digitising after events like Hurricane Katrina, which forced school and college students to miss studies for months.

According to some estimates, in New Orleans alone, 110 of the 126 public schools were completely destroyed and students had to be moved to neighbouring states to complete their education.

Source: https://www.business-standard.com/article/education/edtech-firms-offer-free-access-to-colleges-that-is-impacted-by-coronavirus-120031201574_1.html

2 of Top 5 CBD Consuming Countries in Europe SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 3:00 PM on Thursday, March 12th, 2020

SPONSOR: Mota is seeking to become a vertically integrated global CBD brand. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota. Combined total sales of almost $29,000,000 with a EBITDA of approximately 12.5% (2019) . Click Here for More Info

Mota large
  • These countries are expected to account for virtually all of the legal marijuana sold globally in five years

Marijuana is one of the fastest growing industries on the planet. Legal weed sales have more than tripled between 2014 and 2018, and they’re on track to roughly quadruple between the $10.9 billion generated in licensed cannabis stores 2018 and the projected $40.6 billion in worldwide licensed store sales by 2024. That’s according to the 2019 “State of the Legal Cannabis Markets” report released earlier this year by Arcview Market Research and BDS Analytics.

Yet, what you might find intriguing about this rapid growth is that it’ll wind up being attributed to just a select few countries. Even though more than three dozen countries around the world have legalized medical marijuana, five countries are forecast by Arcview and BDS to account for $38.2 billion of this aforementioned $40.6 billion in licensed-store sales by 2024. Note, licensed-store sales doesn’t include general retailers selling cannabidiol (CBD) products, or cannabinoid-based drug developers selling pot-derived pharmaceuticals.

1. United States: $30.1 billion in cannabis spending by 2024

As should be no surprise, the U.S. projects as the leading marijuana market in the world by sales in 2024. In fact, the $30.1 billion in licensed-store revenue should comprise almost three-quarters of global licensed sales. According to Arcview and BDS, $9 billion of these sales are expected to come from the medical side of the equation, up from $4 billion in 2018, with the remaining $21.1 billion derived from recreational marijuana, up from $5.9 billion last year.

The thing about the U.S. is that cannabis stocks can still thrive even if the federal government doesn’t change its classification of marijuana from Schedule I. As long as Congress and the president continue to respect the right of states to make their own choices on cannabis, the industry could have plenty of runway.

One of the fastest early stage growers looks to be multistate dispensary operator Cresco Labs (OTC:CRLBF). Cresco, which holds the licenses to more than four dozen retail locations in 11 states, made a bold move in April when it announced an all-stock deal to acquire Origin House (OTC:ORHOF). Origin House is one of only a few companies to hold a cannabis distribution license in California, the state responsible for a quarter of all U.S. marijuana spending by 2024. Thus, Cresco Labs’ purchase of Origin House will give it access to more than 500 Californian dispensaries, and over 700 nationwide. Cresco and its vertically integrated peers appear well-positioned to take advantage of this huge growth opportunity.

2. Canada: $5.18 billion by 2024

Despite being the first industrialized country in the world to legalize recreational weed, Canada looks to take a distant second to the United States by 2024 in terms of sales. Arcview and BDS are projecting that $4.8 billion in sales will come from the recreational market by then, with the remainder made up of medical cannabis sales. It’s not uncommon for the medical industry to get cannibalized when adult-use marijuana is legalized, because it means patients no longer have to wait for a doctor’s approval and prescription to buy weed.

There’s a lot of competition in Canada right now, so it’s still unclear which company will be Canada’s kingpin. However, Aurora Cannabis (NYSE:ACB) is a relatively good bet to be near the top of the pack solely based on its production potential. Aurora is already leaps and bounds ahead of its next-closest competitors with an annual run-rate output of 150,000 kilos as of the end of March, and plans to be producing at least 625,000 kilos on a run-rate basis by the end of June 2020. With most of this production located in Canada, and the company sporting a number of large-scale grow farms, Aurora Cannabis should be able to take advantage of economies of scale to drive down its growing costs per gram.

Of course, the real near-term excitement revolves around the upcoming launch of derivative products (e.g,, edibles, vapes, topicals, concentrates, and infused beverages) by mid-December. Derivatives have much better margins and pricing power than dried cannabis flower, which is why Aurora Cannabis and its peers have been busy beefing up their product offerings over the past year in preparation for this upcoming launch date.

3. Germany: $1.35 billion by 2024

Even though Arcview and BDS are not expecting Germany to legalize recreational cannabis, the company’s highly permissive stance toward medical marijuana, and the fact that health insurers cover medical weed in the country, should allow sales to soar from $79 million in 2018 to $1.35 billion by 2024.

Interestingly enough, Canadian cannabis stocks were actually big-time winners of the German cultivation licensing process. Both Aurora Cannabis and Aphria (NYSE:APHA) were awarded licenses to grow cannabis in Germany. For its part, Aphria plans to have an 8,000-square-meter facility in Germany that’ll begin supplying the country with medical marijuana in the early part of 2020. In addition to growing cannabis, Aphria introduced CannRelief in Germany, which is a CBD-based nutraceutical and cosmetics product line. 

As for Aurora Cannabis, its approval to construct a growing facility will allow the company to supply the German market with 4,000 kilos of marijuana over four years, with shipments expected to commence October 2020. Of course, this production capacity is liable to be bumped up if patient demand merits it. 

4. Mexico: $1.02 billion by 2024

Arguably one of the oddest “legality” situations concerning marijuana right now is with Mexico. The nation’s Supreme Court has ruled five times since 2015 that imposing a ban on recreational cannabis is unconstitutional. That’s important, because when Mexico’s Supreme Court reaches five similar decisions on an issue, it becomes the standard throughout the country. Or, in layman’s terms, the Supreme Court has essentially affirmed the legality of recreational marijuana and is simply waiting for lawmakers in the country to hash out the details.

According to Arcview and BDS, Mexico will have legalized adult-use cannabis by 2024, although the ramp-up of legal sales could be slow. By 2024, recreational weed sales are only expected total $582 million, with an additional $441 million in medical spending, for a combined $1.02 billion. Mexico’s considerably larger population than Canada makes for an attractive market opportunity, but it’s unclear how well legal industries will fare with the noted presence of illicit producers.

One company that hasn’t been shy about its push into Mexico is Medical Marijuana, Inc. (OTC:MJNA), the very first publicly listed pot stock. Southern California-based Medical Marijuana was the first company to import CBD-rich oils into Mexico in 2016, giving it a head start on building important relationships with the country’s medical community. You’ll note that even with recreational legalization likely on the horizon, medical spending should continue to grow in Mexico. That gives Medical Marijuana and its RSHO-X hemp oil a real shot to continue penetrating the Mexico’s medical cannabis market. 

5. United Kingdom: $546.9 million by 2024

Although it may not be on track to tip the scales at $1 billion in sales by 2024, the U.K. is poised to be one of the fastest growing countries in the world based on cannabis spending. After only $9.9 million in medical spending last year, Britain is forecast for almost $547 million in medical marijuana revenue by 2024, representing a compound annual growth rate of 95.2%.

This sudden push to legalize and normalize medical pot use in the U.K. can be partially attributed to the success of GW Pharmaceuticals (NASDAQ:GWPH), the cannabinoid-based drug developer that had the U.S. Food and Drug Administration approve the very first cannabis-derived drug last year. GW Pharmaceuticals’ CBD-based oral solution known as Epidiolex dazzled in late-stage studies and wound up reducing seizure frequency for patients with two rare forms of childhood-onset epilepsy by 30% to 40%. Additionally, GW Pharmaceuticals’ Sativex, an oromucosal spray containing both CBD and tetrahydrocannabinol (THC), is approved in more than a dozen markets in Europe (but not the U.S.).

Britain’s citizens and its government have seen what the U.K.-based GW Pharmaceuticals can do with cannabinoids, and its government has been open to the possibility of expanding access to marijuana-based products for medical patients.

Sean Williams has no position in any of the stocks mentioned. The Motley Fool recommends Origin House. The Motley Fool has a disclosure policy.

SOURCE: https://www.fool.com/investing/2019/09/08/5-countries-with-the-highest-cannabis-spending-by.aspx